- According to estimates from 10 analysts, Arrowhead Pharmaceuticals, Inc. stock's average price target has risen from $99.6 to $101.6, with forecasts ranging from $87 to $120 per share
- Based on the Jul. 21 closing price, the updated target implies approximately 36% potential upside
- Consensus rating remains at “Buy” across 14 covering analysts, with 13 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for Arrowhead Pharmaceuticals, Inc. on the , and track all previous and future analyst recommendations for Arrowhead Pharmaceuticals, Inc. in the dedicated .
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.